Teresa Whalen

Company: CytoAgents

Job title: Chief Executive Officer

Seminars:

Evaluating the Impact of Cell Therapy on Patient Safety to Enhance Long-Term Outcomes in B-Cell-Targeted Autoimmune Therapies 12:15 pm

Evaluate clinical safety and monitoring side effects associated with CAR-T therapies Investigate prevention of cytokine released syndrome (CRS) and (ICANS) associated with CAR-T and T-cell engagers Introducing a small molecule oral immune modulator called CTO-1,681, to effectively enhance safety outcomes and expand patient accessRead more

day: Conference Day Two Teal Track